

BEST AVAILABLE COPY

PA 1235274

DEC'D 08 NOV 2004

WIPO

PCT

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

October 12, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/524,097


FILING DATE: November 21, 2003

IB/04/3694

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



Trudie Wallace
TRUDIE WALLACE

Certifying Officer

PTO/SB/16(08-03)

Approved for use through 7/31/2003. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCEUnder the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.**PROVISIONAL APPLICATION FOR PATENT COVER SHEET****This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).**

Express Mail Label No. EV 271824301 US

INVENTOR(S)

Given Name (first and middle (if any))	Family Name or Surname	Residence (City and either State or Foreign Country)
David	McGavin	Kalamazoo, MI
Michael K.	O'Hara	Kalamazoo, MI
Randy D.	Leyh	Groton, CT

AZALIDE ADJUVANT

Direct all correspondence to:

CORRESPONDENCE ADDRESS☒ Customer Number

28523

☐ Firm or
Individual Name

Address

Address

City

State

Zip

Country

Telephone

Fax

ENCLOSED APPLICATION PARTS (check all that apply)

- ☒ Specification Number of Pages 22 ☒ Claims 5
- ☒ Drawing(s) Number of Sheets 2 ☒ Other (specify) Abstract (1 pg.)
- ☒ Application Data Sheet. See 37 CFR 1.76

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

- ☐ Applicant claims small entity status. See 37 CFR 1.27
- ☐ A check or money order is enclosed to cover the filing fees

FILING FEE
AMOUNT(\$)

\$160.00

- ☒ The Director is hereby authorized to charge all required filing fees to, and credit any overpayment to Deposit Account Number: 16-1445
- ☐ Payment by credit card Form PTO-2038 is attached.

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.☐ Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME


Christine S. Lee

DATE: November 21, 2003

REGISTRATION NO 42,788

(if appropriate)

TELEPHONE

(860)686-2144

Docket Number.

PC25320

**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT
ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

22387 U.S. PTO
60/524097

AZALIDE ADJUVANT**Background of the Invention**

The invention provides an adjuvant composition comprising at least one azalide, wherein the azalide acts as an adjuvant. More particularly, the adjuvant composition is a vaccine adjuvant. The invention further provides a vaccine comprising (a) at least one antigen and (b) at least one azalide, wherein the azalide acts as an adjuvant. An adjuvant composition or vaccine of the present invention is useful in the prevention and treatment of diseases caused by a pathogenic agent (*e.g.*, bacteria (*e.g.*, *M. haemolytica*), protozoa, helminths, viruses and fungi), a cancerous cell or an allergen. The use of an azalide as an adjuvant has not yet been reported until Applicants' present invention.

Brief Description of the Drawings


Figure 1. Geometric mean anti-leukotoxin antibody titer for each of the treatment groups.

Figure 2. Least squares mean anti-whole cell antibody titer for each of the treatment groups.

Summary of the Invention

The invention provides an adjuvant composition comprising at least one azalide, wherein the azalide acts as an adjuvant. The azalide may also provide therapeutic (*e.g.*, antibiotic) properties; however, in a preferred embodiment of the invention, the azalide provides little to no antimicrobial therapeutic properties. More particularly, the adjuvant composition is a vaccine adjuvant. The invention further provides a vaccine comprising (a) at least one antigen and (b) at least one azalide, wherein the azalide acts as an adjuvant.

The azalide for use in the present invention acts as an adjuvant, *i.e.*, enhances, increases, upwardly modulates, diversifies or otherwise facilitates an immune response to an antigen. In one embodiment of the invention, the azalide is a 15-membered 9a-azalide having the following formula I:




I

The chemical name of the compound of formula I is (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-((2,6-dideoxy-3-C-methyl-3-O-methyl-4-C-((propylamino)-methyl)- α -L-ribo-hexopyranosyl)oxy-2-ethyl-3,4,1 0-trihydroxy-3,5,8,10,12,14-hexamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one.

In another embodiment of the invention, the azalide is a mixture of azalides. Particularly, the azalide is a mixture of 9a-azalides. More particularly, the azalide is a mixture of 13- and 15-membered 9a-azalides. Even more particularly, the 9a-azalide mixture contains (a) a compound of formula I, as set forth above, and (b) a compound of formula II:

3



II

The chemical name of the 13-membered 9a-azalide of formula II is
 (3R,6R,8R,9R,10S,11S,12R)-11-((2,6-dideoxy-3-C-methyl-3-O-methyl-4-C-((pro
 pylamino)methyl- α -L-ribo-hexopyranosyl)oxy)-2-((1R,2R)-1,2-dihydroxy-1-
 5 methylbutyl)-8-hydroxy-3,6,8,10,12-pentamethyl-9-((3,4,6-trideoxy-3-
 (dimethylamino)- β -D-xylo-hexopyranosyl)oxy)-1-oxa-4-azacyclotridecan-13-one.

More particularly, the 9a-azalide mixture is a composition containing (a) a
 mixture of compounds of formulae I and II, each as set forth above, in a ratio of about,
 respectively, 90% \pm 10% to about 10% \pm 10%; preferably, 90% \pm 4% to about 10% \pm
 10 4%; (b) water; and (c) one or more acids present at a total concentration of from about
 0.2 mmol to about 1.0 mmol per mL of the composition. Such a composition may be
 prepared by heating to a temperature of about 50°C to about 90°C a mixture
 comprising: (i) the compound of formula (I), (ii) water, and (iii) one or more acids in a
 total amount ranging from about 0.2 mmol to about 1.0 mmol per mL of the mixture.

15 More particularly, the 9a-azalide mixture is a composition containing (a) (i) a
 mixture of compounds of formulae I and II, each as set forth above, in a ratio of about,
 respectively, 90% \pm 10% to about 10% \pm 10%; preferably, 90% \pm 4% to about 10% \pm
 4%; (ii) water; and (iii) one or more acids present at a total concentration of from about
 0.2 mmol to about 1.0 mmol per mL of the composition; and (b) one or more water-

miscible co-solvents present in an amount of from about 250 to about 750 mg per mL of the composition. Such a composition may be prepared by heating to a temperature of about 50°C to about 90°C a mixture comprising the compound of formula I or II, each as set forth above, water and one or more acids in an amount ranging from about 0.2 mmol to about 1.0 mmol per mL of the mixture, wherein one or more water-miscible co-solvents is added before, during or after the heating step, in an amount of from about 250 to about 750 mg per mL of the composition. In a preferred embodiment, the water-miscible co-solvent is added after the heating step.

According to the invention, the concentration of the compound of formula I, in the 9a-azalide mixture composition set forth above, before the heating step ranges from about 50 mg per mL to about 500 mg per mL of the mixture. In a preferred embodiment thereof, the concentration ranges from about 50 mg/mL to about 200 mg/mL.

According to the invention, the concentration of the first mixture of compound I and compound II in the 9a-azalide mixture composition set forth above ranges from about 50 mg/mL to about 200 mg/mL of the composition. Particularly, the concentration of the first mixture of compound I and compound II in the 9a-azalide compositions set forth above ranges from about 75 to about 150 mg/mL, and more particularly from about 90 mg/mL to about 110 mg/mL of the composition.

The pH of the mixture ranges from about 5.0 to about 8.0, and more particularly, from about 5.0 to about 6.0. The heating takes place for about 0.5 to about 24 hours, and more particularly, from about 1 to about 8 hours.

Examples of suitable acids for the 9a-azalide mixture compositions set forth above include, but are not limited to, acetic acid, benzenesulfonic acid, citric acid, hydrobromic acid, hydrochloric acid, D- and L-lactic acid, methanesulfonic acid, phosphoric acid, succinic acid, sulfuric acid, D- and L-tartaric acid, p-toluenesulfonic acid, adipic acid, aspartic acid, camphorsulfonic acid, 1,2-ethanedisulfonic acid, laurylsulfuric acid, glucoheptonic acid, gluconic acid, 3-hydroxy-2-naphthoic acid, 1-hydroxy-2-naphthoic acid, 2-hydroxyethanesulfonic acid, malic acid, mucic acid, nitric acid, naphthalenesulfonic acid, palmitic acid, D-glucaric acid, stearic acid, maleic acid,

malonic acid, fumaric acid, benzoic acid, cholic acid, ethanesulfonic acid, glucuronic acid, glutamic acid, hippuric acid, lactobionic acid, lysinic acid, mandelic acid, napadisyllic acid, nicotinic acid, polygalacturonic acid, salicylic acid, sulfosalicylic acid, tryptophanic acid, and mixtures thereof. Particularly, the acid is citric acid. In a
5 more particular embodiment, the citric acid is present in an amount of from about 0.02 mmol to about 0.3 mmol per mL of the composition. More particularly, the acid is a mixture of citric acid and hydrochloric acid. In a more particular embodiment, citric acid is present in an amount of from about 0.02 mmol to about 0.3 mmol per mL of the composition and the hydrochloric acid is present in an amount sufficient to achieve a
10 composition pH of about 5 to about 6.

Examples of a suitable water-miscible co-solvent for the 9a-azalide mixture compositions set forth above include, but are not limited to, ethanol, isopropanol, diethylene glycol monomethyl ether, diethylene glycol butyl ether, diethylene glycol monoethyl ether, diethylene glycol dibutyl ether, polyethylene glycol-300,
15 polyethylene glycol-400, propylene glycol, glycerine, 2-pyrrolidone, N-methyl 2-pyrrolidone, glycerol formal, dimethyl sulfoxide, dibutyl sebecate, polysorbate 80, and mixtures thereof. Particularly, the one or more water-miscible co-solvents is propylene glycol. More particularly, the propylene glycol is present in an amount of from about 450 to about 550 mg per mL of the composition.

20 In another particular embodiment, the one or more acids are citric acid present in an amount of from about 0.02 mmol to about 0.3 mmol per mL of the composition and hydrochloric acid is present in an amount sufficient to achieve a composition pH of about 5 to about 6; the one or more water-miscible co-solvents is propylene glycol present in an amount of from about 450 to about 550 mg per mL of the composition;
25 and the azalide composition further comprises the antioxidant monothioglycerol present in an amount of from about 4 mg/mL to about 6 mg/mL of the composition.

According to the invention, the antigen can be any antigen which in combination with the azalide elicits an enhanced, increased, upwardly modulated, diversified or otherwise facilitated immune response. Particularly the antigen
30 stimulates the production of a specific antibody or antibodies that can combine with the

antigen; and/or the antigen stimulates the generation of lymphocytes specific for the antigen, said lymphocytes then being able to react against the antigen by the production of lymphokines that regulate and stimulate effector functions that can be targeted against the antigen or by the production of cells that can specifically react with the antigen.

- 5 Examples of suitable antigens are defined below. Particularly, the antigen is a *M. haemolytica* antigen, a *M. haemolytica* leukotoxin, a *M. haemolytica* capsular antigen, or a *M. haemolytica* soluble antigen, each as defined herein, or a mixture thereof (e.g., the One Shot[®] antigen, commercially available from Pfizer, Inc., New York).

- 10 The invention provides a method for enhancing, increasing, upwardly modulating, diversifying or otherwise facilitating an immune response to an antigen comprising administration of an adjuvant composition or vaccine adjuvant of the invention.

- 15 The invention provides a method for enhancing, increasing, upwardly modulating, diversifying or otherwise facilitating an immune response to an antigen comprising administration of a vaccine of the invention.

The invention further provides a method of treating disease caused by a pathogenic agent, a cancerous cell, or an allergen comprising the step of administering an adjuvant composition or vaccine adjuvant of the present invention.

- 20 The invention further provides a method of treating disease caused by a pathogenic agent, a cancerous cell, or an allergen comprising the step of administering a vaccine of the present invention.

The invention further provides a method of preventing disease caused by a pathogenic agent, a cancerous cell, or an allergen comprising the step of administering an adjuvant composition or vaccine adjuvant of the present invention.

- 25 The invention further provides a method of preventing disease caused by a pathogenic agent, a cancerous cell, or an allergen comprising the step of administering a vaccine of the present invention.

- 30 An adjuvant composition or vaccine adjuvant of the invention can be used in the manufacture of a medicament for the prophylactic treatment of a disease caused by a pathogenic agent, a cancerous cell, or an allergen.

An adjuvant composition or vaccine adjuvant of the invention can be used in the manufacture of a medicament for the therapeutic treatment of a disease caused by a pathogenic agent, a cancerous cell, or an allergen.

5 A vaccine of the invention can be used in the manufacture of a medicament for the prophylactic treatment of a disease caused by a pathogenic agent, a cancerous cell, or an allergen.

A vaccine of the invention can be used in the manufacture of a medicament for the therapeutic treatment of a disease caused by a pathogenic agent, a cancerous cell, or an allergen.

10

Definitions

As used herein, the article "a" or "an" refers to both the singular and plural form of the object to which it refers.

15 As used herein, the term "adjuvant", unless indicated otherwise, refers to any substance or mixture of substances that enhances, increases, upwardly modulates, diversifies or otherwise facilitates the immune response (*e.g.*, humoral or cellular immune response) to an antigen.

20 As used herein, the term "antigen", unless indicated otherwise, refers to any agent that, when introduced into an immunocompetent human or animal, stimulates a humoral and/or cell mediated immune response. The antigen may be a pure substance, a mixture of substances, or particulate material (including cells or cell fragments) or a live, usually attenuated, organism or virus. Examples of suitable antigens include, but are not limited to, a protein, glycoprotein, lipoprotein, peptide, carbohydrate/polysaccharide, lipopolysaccharide, toxin, virus, bacterium, fungus, and
25 parasite. Other suitable antigens include minimal components of an antigen such as, but not limited to, an antigenic determinant or epitope. Still other suitable antigens include those described in U.S. Patent No. 5,855,894. An antigen may be native (naturally expressed or made), synthetic or derived by recombinant DNA methodologies familiar to those skilled in the art.

30

As used herein, the term "azalide", unless indicated otherwise, refers to the class of compounds characterized by sugar(s)-substituted nitrogen-containing macrocyclic lactone rings. Examples of suitable azalides include, but are not limited to, 8a- and 9a-azalides and mixtures thereof. Particularly, the azalide is an 8a-azalide, a
5 9a-azalide or a mixture thereof. Examples of suitable 8a-azalides include, but are not limited to, those described in U.S. Patent 6,054,434. Examples of suitable 9a-azalides include, but are not limited to, those described in U.S. Patent Nos. 6,339,063 and 6,514,945.

As used herein, the term "leukotoxin", unless indicated otherwise, refers to any
10 compound toxic to leukocytes. For example, the leukotoxin can be a soluble toxin produced by actively growing *Mannheimia (Pasteurella) haemolytica* as taught in the literature. See e.g., U.S. Pat. No. 5,055,400; Canadian patent application 91000097 and Gentry *et al.*, "Neutralizing monoclonal antibodies to *P. haemolytica* leukotoxin affinity-purify the toxin from crude culture supernatants" Microbial Pathogenesis, 10:
15 411-417 (1991). "Leukotoxoid" is the term used to describe inactivated leukotoxin. Leukotoxin is alternately referred to in the literature by other identifiers as exotoxin or cytotoxin.

As used herein, "capsular antigen", unless indicated otherwise, refers to any of the antigens, usually polysaccharide in nature, that are carried on the surface of
20 bacterial capsules. Capsular antigen may alternatively referred to as a capsular polysaccharide or capsular substance. For example, a capsular antigen can be a soluble capsular polysaccharide from *M. (P.) haemolytica* as described in the literature. See e.g. Inzana, T. J., "Capsules and Virulence in the HAP Group of Bacteria" Can J of Vet Research, 54:S22-S27 (1990); and Adlam *et al.*, "Purification, characterization and
25 immunological properties of the serotype-specific capsular polysaccharide of *Pasteurella haemolytica* (serotype A1) organisms" J Gen Microbiol, 130:2415-2426 (1984).

As used herein, "soluble antigen", unless indicated otherwise, refers to any antigen(s) from any source that exists or can exist in a soluble state. For example, a
30 soluble antigen can be a soluble antigen shed during growth of *M. (P.) haemolytica*

other than leukotoxin and capsular antigen such as glycoprotease and neuraminidase. See *e.g.* Reggie *et al.* "Molecular Studies of Ssal, a Serotype-Specific Antigen of *Pasteurella haemolytica* A1", Infection and Immunity, Vol. 59 No.10 3398-3406 (1991).

5 As used herein, the term "tulathromycin", unless indicated otherwise, refers to 9a-azalide mixture composition containing (a)(i) a mixture of compounds of formulae I and II, each as set forth above, in a ratio of about $90\% \pm 4\%$ to about $10\% \pm 4\%$, respectively; (ii) water; and (iii) one or more acids present at a total concentration of from about 0.2 mmol to about 1.0 mmol per mL of the composition; and (b) one or
10 more water-miscible co-solvents present in an amount of from about 250 to about 750 mg per mL of the composition.

 As used herein, the term "vaccine", unless indicated otherwise, refers to any preparation of antigen or immunogenic material suitable for the stimulation of active immunity in animals or humans. An azalide composition or vaccine adjuvant of the
15 present invention may be used in such a preparation.

Detailed Description of the Invention

The azalide for use in the present invention, as set forth above, may be commercially available or prepared by using organic chemical reactions and techniques
20 known in the art, including the methods described above. For example, the azalide of formula I, as set forth above, can be formed from a translactonization reaction of the azalide of formula II, as set forth above. Likewise, the azalide of formula II can be formed from a translactonization reaction of the azalide of formula I. Mixtures of the azalide of formulae I and II can be obtained from either a compound of formula I or
25 formula II upon equilibration in an aqueous solution. Methods for obtaining the azalide of formula I are described in International publication no. WO 98/56802. Methods for obtaining the azalide of formula II are described in U.S. Patent No. 6,514,945. Other methods for preparing azalides are described in U.S. Patent Nos. 6,054,434 and 6,339,063 as well as the methods described in the examples set forth
30 below.

A vaccine of the present invention may be prepared by any means known in the art including the procedure set forth in Example 1 below. Particularly, a vaccine may be prepared by combining at least one azalide with at least one antigen, each as set forth herein. More particularly, the antigen is in freeze-dried form and is reconstituted
5 with at least one azalide solution acting as an adjuvant just prior to use. Alternatively, a solid (e.g., powder) azalide (e.g., a compound of either formula I or II) is combined with an aqueous antigen solution to form the vaccine.

An adjuvant composition, vaccine adjuvant or vaccine of the present invention may further contain additional agents. For example, additional antigens may be
10 present. For example, an adjuvant composition, vaccine adjuvant or vaccine of the present invention may contain a combination of antigens from *Pasteurella multocida*, *Haemophilus somnus*, Clostridial species, Mycoplasma species, Bovine Respiratory Syncytial Virus, Bovine Viral Diarrhea Virus, and/or Bovine Parainfluenza Type 3 virus, or any other infectious agent or derivative thereof. An adjuvant composition,
15 vaccine adjuvant or vaccine of the present invention can also contain antigen(s) related to, derived from, or identical to, an antigen from a cancer cell or an allergen.

The adjuvant composition, vaccine adjuvant or vaccine of the present invention may further comprise one or more antioxidants present in an amount of from about 0.01 mg to about 10 mg per mL of the composition. Particularly, the one or more
20 antioxidants is selected from the group consisting of sodium bisulfite, sodium sulfite, sodium metabisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, L-ascorbic acid, erythorbic acid, acetylcysteine, cysteine, monothioglycerol, thioglycollic acid, thiolactic acid, thiourea, dithiothreitol, dithioerythritol, glutathione, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, nordihydroguaiaretic
25 acid, propyl gallate, .alpha.-tocopherol, and mixtures thereof. More particularly, the one or more antioxidants is monothioglycerol. In another particular embodiment, monothioglycerol is present in an amount of from about 4 mg/mL to about 6 mg/mL of the composition.

The adjuvant composition, vaccine adjuvant or vaccine of the present invention may further comprise one or more preservatives in an amount of from about 0.01 to about 10 mg per mL of the composition. Examples of suitable preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, methylparaben, ethylparaben, propylparaben, butylparaben, sodium benzoate, phenol, and mixtures thereof. As would be understood by one of skill in the art, the presence or absence of a preservative will depend upon the antigen. For example, if the antigen is a live bacterial antigen, then no preservative would be added.

The adjuvant composition, vaccine adjuvant or vaccine of the present invention may further comprise an additional non-azalide adjuvant. Examples of suitable non-azalide adjuvants include those known in the art.

An adjuvant composition of the invention may be administered as part of a vaccine formulation, which may optionally contain an additional adjuvant, hereinafter referred to as "co-administration". Alternatively, an adjuvant composition of the invention may be administered in addition to, *i.e.*, separately, a vaccine, which may optionally contain an additional adjuvant hereinafter referred to as "concurrent administration". The "additional adjuvant" being an adjuvant other than the adjuvant composition of the invention. Regardless of mode of administration, the azalide acts as an adjuvant or provides an adjuvant effect, *i.e.*, elicits an enhanced, increased, upwardly modulated, diversified or otherwise facilitated immune response to an antigen.

The adjuvant composition, vaccine adjuvant or vaccine of the present invention may be used to prevent or treat diseases in humans or animals caused by a pathogenic agent, a cancerous cell, or an allergen by the administration of a therapeutically effective amount of the adjuvant composition or vaccine to the human or animal suffering from the disease.

According to the invention, the pathogenic agent may be any pathogenic agent including, but not limited to, bacteria, protozoa, helminths, viruses and fungi. Diseases in animals caused by such pathogenic agents include, but are not limited to, bovine respiratory disease, swine respiratory disease, pneumonia, pasteurellosis, coccidiosis,

anaplasmosis, and infectious keratitis. Thus, the adjuvant compositions and vaccine adjuvants of the invention can be used to prevent or treat, *inter alia*, bovine respiratory disease, swine respiratory disease, pneumonia, pasteurellosis, coccidiosis, anaplasmosis, and infectious keratitis.

5 According to the invention, the cancerous cell may be any type of cancerous cell in the art. According to the invention, the allergen may be any allergen known in the art.

 The adjuvant composition, vaccine adjuvant or vaccine of the invention can be used to protect or treat both livestock animals and domestic animals including, but not
10 limited to, cattle, horses, sheep, swine, goats, rabbits, cats, dogs, and other mammals in need of treatment. The adjuvant composition, vaccine adjuvant or vaccine of the invention can be also used to protect or treat humans. As would be understood by one of skill in the art, the adjuvant composition and/or vaccine of the invention to be administered will be chosen based on the patient to be protected or treated. Thus, as
15 would be understood by one of skill in the art, an adjuvant composition, vaccine adjuvant or vaccine of the invention used for the protection or treatment of animals may differ from the adjuvant composition, vaccine adjuvant or vaccine of the invention used for the protection or treatment of humans.

 The adjuvant composition, vaccine adjuvant or vaccine may be administered
20 through oral, intramuscular, intravenous, subcutaneous, intra-ocular, parenteral, topical, intravaginal, or rectal routes. For administration to cattle, swine or other domestic animals, the adjuvant compositions or vaccine adjuvants may be administered in feed or orally as a drench composition. Particularly, the adjuvant composition, vaccine adjuvant or vaccine is injected intramuscularly, intravenously or subcutaneously.

25 For purposes of this invention, a therapeutically effective amount is that amount which enhances, increases, upwardly modulates, diversifies or otherwise facilitates an immune response to an antigen. Particularly, a therapeutically effective amount is that amount which induces immunity in the animal suffering from the disease caused by the pathogenic agent, cancerous cell, or allergen. As would be
30 understood by one of skill in the art, a therapeutically effective amount will vary and be

determined on a case-by-case basis. Factors to be considered are the same as those outlined below for determining proper dosages. For example, a therapeutically effective amount can be readily determined by testing a variety of adjuvant compositions or vaccine preparations made in accordance with this invention in cattle and selecting the composition or vaccine preparation that induced immunity in a statistically significant number of cattle when challenged with *M. (P.) haemolytica*. A vaccine induced immunity can be measured by resistance to experimental challenge reflected by decreased or absence of mortality, absence of, or minimal clinical signs, reduction or complete elimination of characteristic lung lesions as is known to those in the art.

Particularly, the adjuvant composition or vaccine adjuvant, whether co-administered or concurrently administered, may be administered in dosages ranging from about 0.01 mg of the equilibrium mixture of compounds per kg of body weight (mg/kg) to about 20 mg/kg. More particularly, the adjuvant composition or vaccine adjuvant, whether co-administered or concurrently administered, may be administered in dosages ranging from about 1 mg/kg to about 10 mg/kg. Even more particularly, the adjuvant composition or vaccine adjuvant, whether co-administered or concurrently administered, are administered in dosages ranging from about 1.25 mg/kg to about 5.0 mg/kg. The adjuvant composition or vaccine adjuvant, whether co-administered or concurrently administered, may be administered continuously, intermittently or as a single dose. Those of skill in the art will readily recognize that variations in dosages and length of treatment can occur depending upon the species, weight and condition of the subject being treated, its individual response to the adjuvant compositions and vaccines, and the particular route of administration chosen. In some instances, dosage levels below the lower limit of the aforesaid ranges may be therapeutically effective, while in other cases still larger doses may be employed without causing any harmful side effects, provided that such larger doses are first divided into several small doses for administration throughout the day. A booster dose is believed desirable whenever subsequent stress or exposure is likely. The mode of administration of the adjuvant compositions or vaccine adjuvants, whether co-administered or concurrently

administered, may be any suitable route which delivers the adjuvant compositions, whether co-administered or concurrently administered, to the host. Subcutaneous administration or administration by intramuscular injection is preferred.

- The following Examples further illustrate the compositions and methods of the present invention. It is to be understood that the present invention is not limited to the specific details of the Examples provided below.

Example 1

Vaccine preparations and treatments

- 10 An expired, commercial *Mannheimia haemolytica* vaccine (One Shot[®], commercially available from Pfizer, Inc., New York) antigen was used as a model antigen in these studies. This antigen was reconstituted using One Shot[®] adjuvant, sterile water or tulathromycin. Saline was used as a negative control. Vaccine efficacy was evaluated by serology and by challenge with a virulent isolate of *M.*
- 15 *haemolytica*. Forty beef calves weighing an average of 478 pounds on Day -1 were enrolled in the study. Calves were selected based on having low antibody titers to leukotoxin. Treatment study groups are shown in Table 1.

Table 1. Vaccine and treatment groups.

Treatment Group	Vaccine	Dose Volume	Route	Number of animals vaccinated
T01	Saline	2 ml	SC	10
T02	One Shot [®] vaccine	2 ml	SC	10
T03	One Shot [®] antigen reconstituted in sterile water	2 ml	SC	10
T04	One Shot [®] antigen reconstituted in tulathromycin	5.3 ml	SC	10

This study was designed to evaluate the adjuvant properties of the 9a-azalide tulathromycin by replacing the adjuvant in a commercial *Mannheimia haemolytica* vaccine (One Shot[®]) with tulathromycin.

- 5 Each animal was injected subcutaneously on the left side of the neck on Day 0. A 2-ml dose of saline solution was administered to each animal in T01. One Shot[®] *Mannheimia (Pasteurella) haemolytica* Bacterin-Toxoid was reconstituted in One Shot[®] adjuvant and administered to the T02 calves. The vaccine was reconstituted using sterile water and administered to T03 animals. One Shot[®] *Mannheimia*
10 *(Pasteurella) haemolytica* Bacterin-Toxoid was reconstituted in tulathromycin. The mean body weight of the calves in T04 on Day -1 was 471.1 pounds. A volume of 5.3 ml of tulathromycin was used per dose to reconstitute the vaccine and was administered to each calf in T04.
- 15 For these studies animals were allocated to treatments per a randomized complete block design. The blocking factor was based upon leukotoxin serology titers obtained prior to the start of the study. Serology data was summarized by time-point. A log transformation $\{\ln(n+1)\}$ was applied to titer values prior to analysis. Linear combinations of the parameter estimates were used in *a priori* contrasts after
20 testing for either a significant ($P \leq 0.05$) treatment effect or interaction effect between time-point and treatment. Comparisons were made between treatments at each time-point. The 5% level of significance ($P \leq 0.05$) was used to assess statistical differences. 95% confidence intervals for each of the mean values were also calculated. For titer values, geometric means at each sampling time-point were
25 calculated from least squares means of the $\ln(\text{titer values}+1)$.

Example 2

Post-vaccination Serology

- Serum anti-leukotoxin antibodies were monitored after vaccination (See Table 2;
30 Figure 1). Following vaccination the anti-leukotoxin mean antibody level in ng of IgG

(See Confer, *et al.*, "Serum antibody responses of cattle to iron-regulated outer membrane proteins of *Pasteurella haemolytica* A1" Vet Immunol Immunopathol Vol. 47, pp 101-110 (1995)) significantly increased by Day 7 in both T02 and T04 compared to the controls and remained higher throughout the study ($P \leq 0.05$). On Days 5 14 and 21, the T04 mean anti-leukotoxin antibodies were significantly higher than those in T02 ($P \leq 0.05$). Although the mean antibody levels remained higher in T04 compared to T02 for the rest of the study, the difference between the two groups decreased. The level of anti-leukotoxin antibodies in T01 was relatively unchanged during the study. The antibody levels in T03 were not significantly different from the 10 T01 levels on any of the sample days ($P > 0.05$).

Anti-whole cell antibodies were also monitored (Table 3 and Figure 2). On Days 7 and 14, the T02 and T04 mean anti-whole cell antibody levels in ng of IgG were significantly greater compared to T01 ($P \leq 0.05$). The mean antibody levels for T04 15 remained significantly higher than the T01 means for the rest of the study ($P \leq 0.05$). On days 14 and 21, the T04 mean antibody levels were significantly higher than those from T02 ($P \leq 0.05$). As observed with the anti-leukotoxin antibody levels, the difference between the T02 and T04 whole cell antibody levels decreased during the rest of the study. The mean antibody levels in T01 increased slightly during the study. 20 The whole cell antibody levels in T03 were not significantly different from the T01 levels on any of the sample days ($P > 0.05$).

Table 2. Anti-leukotoxin geometric mean antibody titer for each treatment group.

Treatment Group	Study Day				
	0	7	14	21	28
T01	0.122 ^a	0.141 ^a	0.127 ^a	0.263 ^a	0.201 ^a
T02	0.131 ^a	0.573 ^b	0.892 ^b	0.778 ^b	0.701 ^b
T03	0.101 ^a	0.263 ^{ab}	0.388 ^a	0.468 ^{ab}	0.293 ^a
T04	0.114 ^a	0.479 ^b	1.542 ^c	1.382 ^c	1.078 ^b

Means within columns with different superscripts are significantly different ($P \leq 0.05$).

Table 3: Anti-whole cell geometric mean antibody titer for each treatment group.

Treatment Group	Study Day				
	0	7	14	21	28
T01	0.149 ^a	0.154 ^a	0.164 ^a	0.222 ^a	0.249 ^a
T02	0.125 ^a	0.399 ^b	0.562 ^b	0.541 ^a	0.524 ^{ab}
T03	0.158 ^a	0.262 ^{ab}	0.320 ^{ab}	0.382 ^a	0.208 ^a
T04	0.151 ^a	0.413 ^b	1.236 ^c	1.180 ^b	0.907 ^b

5 Means in a column with different superscripts are significantly different ($P \leq 0.05$)

Example 3

Post-Challenge Clinical Observations

For the vaccination challenge, 5 ml of a virulent culture of *M. haemolytica* (Oklahoma State strain) was administered by transthoracic injection into the right and left caudal lung lobes of each calf (10 ml of culture per calf) on Day 34 of the study. The inoculum contained approximately 5.6×10^8 CFU/ml.

15 Clinical scores (Appendix 2) were assessed prior to challenge on Day 33 and once daily for the duration of the study. These scores reflected an assessment of attitude and respiratory effort. The least squares mean percentage of post-challenge days with at least one clinical score >0 for each of the assessments is summarized in Table 4. The mean percentages were not different in the groups for attitude although T04 was the lowest. ($P > 0.05$). The percentage of days with respiratory effort scores of >0 was significantly less in T04 when compared with the other groups ($P \leq 0.05$).

Table 4. Least squares mean percentage of post-challenge days with a clinical score >0 by clinical sign.

Treatment Group	Clinical Sign % of Days	
	Attitude	Respiratory Effort
T01	63.1	48.2 ^a
T02	56.4	45.8 ^a
T03	52.7	48.9 ^a
T04	41.6	19.4 ^b

Means in a column with different superscripts are significantly different ($P \leq 0.05$).

5

The mean percentage of lung consolidation for each group is summarized in Table 5. One animal in T01 died immediately following challenge due to pulmonary hemorrhage as a result of challenge administration; thus its lung lesion data was excluded from the analysis. One animal in T03 was found dead on Day 37 as a result of severe pneumonia but was necropsied and its lung data was analyzed along with the data from the other animals. There were no significant differences between the treatment groups ($P > 0.05$). Both T02 and T04 had fewer lung lesions compared with the control while T03 had increased lesions.

10

Table 5. Least squares mean of percentage of lung lesions.

Treatment Group	<i>n</i>	Least Squares Mean Percentage Lung Lesions	Range of Lung Lesion Percentage
T01	9	12.8	3.6-30.0
T02	10	10.0	4.6-32.8
T03	10	21.2	8.8-61.8
T04	10	9.1	2.5-31.5

15

Following challenge, animals in all groups showed typical symptoms of respiratory disease. The groups receiving complete vaccine or antigen plus tulathromycin had fewer lung lesions compared to the control group. The group receiving just the antigen without adjuvant had increased lung lesions compared with the other groups.

- 5 Tulathromycin appeared to effectively replace the adjuvant in One Shot® vaccine, demonstrating the adjuvant function of tulathromycin.

Appendix

Clinical Scoring System

Clinical Evaluation	Clinical Scores
Attitude	<p>0 = Normal. Alert, active, stands, moves and responds to stimuli quickly and steadily, shows continuous interest in surroundings.</p> <p>1 = Mild. Lethargic and somnolent, stands, moves and responds to stimuli slowly and unsteadily, holds head low, lies down occasionally.</p> <p>2 = Moderate. Tends to lie down frequently, lethargic and somnolent, stands, moves and responds to stimuli reluctantly and unsteadily, holds head low, staggers, shows little interest in surroundings.</p> <p>3 = Severe. Recumbent or shows little or no response to stimuli or stands/moves with difficulty. <u>Animal should be euthanized for humane reasons.</u></p>
Respiratory effort	<p>0 = Normal. Respirations are shallow and mostly thoracic (difficult to see at a distance of approximately 10 feet).</p> <p>1 = Slight. Respirations are deep and largely abdominal (easy to see at a distance of approximately 10 feet).</p> <p>2 = Marked. Respirations are labored and entirely abdominal.</p> <p>3 = Severe. Respirations are very labored or animal grunts during breathing. <u>Animal should be euthanized for humane reasons.</u></p>

Conclusion

As illustrated by Examples 1-4, T04 was as good if not better than T02 as exhibited by higher antibody production, better attitude and respiratory effect, and fewer lung lesions - all of which are indicators of an immune response to an antigen. Further confirmation of adjuvant properties of tulathromycin is illustrated by comparing T04 results against T03 results. Still further confirmation can be found in T01 and T03 antibody results, which indicate that over the same amount of time (compared to T02 and T04), there was little to no change in antibody production.

10

Example 5

Azalide Preparation

One thousand liters of an injectable pharmaceutical composition containing 100 mg of an equilibrium mixture of compounds I and II per mL of composition were prepared as follows.

15

Approximately 400 liters of Water for Injections (United States Pharmacopeia (USP)/Pharmacopoeia Europa (Ph. Eur.) grade) was added to a stainless steel compounding vessel. Nitrogen (United States National Formulary (NF)/Ph. Eur. grade) was bubbled through the water and agitation was begun. Nitrogen (NF/Ph. Eur. grade) was also used as an overlay to reduce oxygen exposure of the solution in the compound vessel throughout manufacture. The solution was agitated throughout manufacture except during the final sampling and volume check. 19.2 kg of anhydrous citric acid (USP/Ph. Eur. grade) was added to the water. The resulting mixture was agitated until the acid dissolved. 7.8 kg of concentrated hydrochloric acid (NF/Ph. Eur. grade), was added to the mixture and dispersed. 103.0 kg of a mixture containing approximately 97% of compound I and compound II in a ratio exceeding 99:1 and approximately 3% of one or more impurities was added to the agitating mixture over a period of approximately one hour. The total amount of compound I and compound II added to the solution was 100.0 kg. The formulation was agitated until dissolution of

20

25

the mixture of compound I, compound II, and the one or more impurities appeared complete. Agitation was continued for approximately one hour after dissolution appeared complete. The pH of the resulting solution was adjusted to 7.0 ± 0.3 by adding a total of 0.25 kg of concentrated hydrochloric acid (NF/Ph. Eur. grade) in multiple portions. Equilibration of compound I and compound II was achieved at elevated temperature. The temperature of the solution was raised to 60 ± 3 °C which took approximately 15 minutes. The solution was held at 60 ± 3 °C for approximately 120 minutes. At the end of this period, the ratio of compound I to compound II was approximately 90:10 as determined by HPLC. The solution was then cooled to approximately 25 °C which took approximately 45 minutes. 500 kg of propylene glycol (USP/Ph. Eur. grade) was added to the solution and dispersed. Nitrogen (NF/Ph. Eur. grade) was bubbled through the solution. 5.0 kg of monothioglycerol (NF grade) was added to the solution and dispersed. 10.5 kg of concentrated hydrochloric acid (NF/Ph. Eur. grade), was added to the mixture and dispersed. The pH of the solution was adjusted to 5.4 ± 0.3 by addition of approximately 0.85 kg of concentrated hydrochloric acid (NF/Ph. Eur. grade) in multiple portions. Sufficient Water for Injections (USP/Ph. Eur. grade) was added to produce a final volume of 1000 liters. The resulting composition contained 100 mg of an equilibrated mixture of compounds I and II per mL of composition, 500 mg of propylene glycol per mL of the composition, 5.0 mg of monothioglycerol per mL of the composition, and 19.2 mg (0.100 millimole) of citric acid per mL of the composition.

The composition was filtered through 0.2 micron Millipore Milligard (Millipore Corporation, Billerica, Massachusetts, USA) pre-filter into a stainless steel receiving tank and held for approximately 60 hours. The composition was sterilized by filtering it through redundant 0.2 micron Millipore Durapore (Millipore SA, Molsheim France) sterilizing filters. The sterilizing filters were sterilized by moist heat autoclaving for 45 minutes at 122 °C. The filters were tested for integrity using both bubble point and diffusion test methods prior to their sterilization and after being used for filtration of the solution. 20 mL flint, type I glass serum vials (Saint Gobain des Jonquieres, Mers


les Bains, France) were sterilized and depyrogenated in a dry heat tunnel with a set point of 350 °C. The minimum exposure time was 31 minutes. 20 mm chlorobutyl rubber stoppers coated with Daikyo Fluoro Resin-D (Daikyo-Seiko, Tokyo, Japan) were depyrogenated by washing and sterilized by moist-heat autoclaving for 60 minutes at 124 °C. Each of 1444 of the 20 mL vials was filled under sterile conditions with 20.6 mL of the resulting composition. Each vial contained 2.06 g of an equilibrated mixture of compounds I and II. The vial headspace was flushed with nitrogen and the vials were sealed with the stoppers and appropriate aluminum overseals (Helvoet Pharma, Alken, Belgium). 500 mL flint, type I glass serum vials (Saint Gobain des Jonquieres, Mers les Bains, France) were sterilized and depyrogenated in a dry heat tunnel with a set point of 350 °C. The minimum exposure time was 38 minutes. 32 mm chlorobutyl rubber stoppers coated with Daikyo Fluoro Resin-D (Daikyo-Seiko, Tokyo, Japan) were depyrogenated by washing and sterilized by moist-heat autoclaving for 60 minutes at 124 °C. Each of 1537 of the 500 mL vials was filled under sterile conditions with 510 mL of the resulting composition. Each vial contained 51.0 g of an equilibrated mixture of compounds I and II. The vial headspace was flushed with nitrogen and the vials were sealed with the stoppers and appropriate aluminum overseals (Helvoet Pharma, Alken, Belgium).

All publications, including but not limited to, issued patents, patent applications, and journal articles, cited in this application are each herein incorporated by reference in their entirety.

Although the invention has been described above with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention. It should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

The claimed invention is:


1. Adjuvant composition comprising at least one azalide selected from the group consisting of an 8a-azalide and a 9a-azalide, wherein said azalide acts as an adjuvant.
2. An adjuvant composition of claim 1, wherein said azalide is an 8a-azalide.
3. An adjuvant composition of claim 1, wherein said azalide is a 9a-azalide.
4. An adjuvant composition of claim 3, wherein said 9a-azalide is a compound of
10 formula I:



I

5. An adjuvant composition of claim 4, further comprising a compound of
15 formula II:

24




II

6. An adjuvant composition of claim 5, wherein said 9a-azalide is a composition comprising (a) a mixture of compounds of formulae I and II in a ratio of about 90% ± 10% to about 10% ± 10%, respectively; (b) water; and (c) one or more acids present at a total concentration of from about 0.2 mmol to about 1.0 mmol per mL of the
7. An adjuvant composition of claim 5, wherein said 9a-azalide is a composition comprising (a)(i) a mixture of compounds of formulae I and II in a ratio of about 90% ± 10% to about 10% ± 10%, respectively; (ii) water; and (iii) one or more acids present at a total concentration of from about 0.2 mmol to about 1.0 mmol per mL of the composition; and (b) one or more water-miscible co-solvents present in an amount of from about 250 to about 750 mg per mL of the composition.
8. An adjuvant composition of one of claims 1-7, wherein the composition is a vaccine adjuvant.

9. A method for enhancing, increasing, upwardly modulating, diversifying or otherwise facilitating an immune response in an animal to an antigen comprising administration of the adjuvant composition of one of claims 1-8 to the animal.
- 5 10. Method of preventing a disease caused by a pathogenic agent, cancerous cell, or allergen in an animal comprising the step of administering the adjuvant composition of one of claims 1-8 to the animal suffering from the disease.
11. Method of treating a disease caused by a pathogenic agent, cancerous cell, or
10 allergen in an animal comprising the step of administering the adjuvant composition of one of claims 1-8 to the animal suffering from the disease.
12. A vaccine comprising (a) at least one antigen and (b) at least one azalide, wherein said azalide acts as an adjuvant.
- 15 13. A vaccine of claim 12, wherein said azalide is an 8a-azalide.
14. A vaccine of claim 12, wherein said azalide is a 9a-azalide.
- 20 15. A vaccine of claim 14, wherein said 9a-azalide is a compound of formula I:

PC25320


26



I

16. A vaccine of claim 15, further comprising a compound of formula II:

5



II

17. A vaccine of claim 16, wherein said 9a-azalide is a composition comprising (a) a mixture of compounds of formulae I and II in a ratio of about $90\% \pm 10\%$ to about $10\% \pm 10\%$, respectively; (b) water; and (c) one or more acids present at a total concentration of from about 0.2 mmol to about 1.0 mmol per mL of the composition.
- 5
18. A vaccine of claim 16, wherein said 9a-azalide is a composition comprising (a)(i) a mixture of compounds of formulae I and II in a ratio of about $90\% \pm 10\%$ to about $10\% \pm 10\%$, respectively; (ii) water; and (iii) one or more acids present at a total concentration of from about 0.2 mmol to about 1.0 mmol per mL of the composition; 10 and (b) one or more water-miscible co-solvents present in an amount of from about 250 to about 750 mg per mL of the composition.
19. A vaccine of one of claims 12-18, wherein said antigen is selected from the group consisting of a *M. haemolytica* antigen, a *M. haemolytica* leukotoxin, a *M.* 15 *haemolytica* capsular antigen, a *M. haemolytica* soluble antigen, or a mixture thereof.
20. A method for enhancing, increasing, upwardly modulating, diversifying or otherwise facilitating an immune response in an animal to an antigen comprising administration of the vaccine of one of claims 12-19 to the animal.
- 20
21. Method of preventing a disease caused by a pathogenic agent, a cancerous cell or an allergen in an animal comprising the step of administering the vaccine of one of claims 12-19 to the animal suffering from the disease.
- 25
22. Method of treating a disease caused by a pathogenic agent, a cancerous cell, or an allergen in an animal comprising the step of administering the vaccine of one of claims 12-19 to the animal suffering from the disease.


Abstract

The invention describes an adjuvant composition comprising at least one azalide, wherein the azalide acts as an adjuvant. More particularly, the adjuvant composition is a vaccine adjuvant. The invention further describes a vaccine
5 comprising (a) at least one antigen and (b) at least one azalide, wherein the azalide acts as an adjuvant. An adjuvant composition or vaccine of the present invention is useful in the prevention and treatment of diseases caused by a pathogenic agent, a cancerous cell, or an allergen.

PC25320

AZALIDE ADJUVANT
David McGavin, et al.
PC25320

5



10

Figure 1. Geometric mean anti-leukotoxin antibody titer for each of the treatment groups.

PC25320

AZALIDE ADJUVANT
David McGavin, et al.
PC25320

5

10




Figure 2. Least squares mean anti-whole cell antibody titer for each of the treatment groups.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.